Caribou Biosciences, Inc.
Data quality: 100%
CRBU
NASDAQ
Manufacturing
Chemicals
$2.15
▼
$0.05
(-2.27%)
6 months return
—
Momentum
Neutral
5Y revenue growth
3.84%
Growth
Revenue Growth (5Y)
3.84%
Above sector avg (1.82%)
Revenue (1Y)11.66%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-96.19%
Below sector avg (-54.47%)
ROIC-65.30%
Net Margin-1327.40%
Op. Margin-1329.37%
Safety
Debt / Equity
N/A
Current Ratio5.54
Interest CoverageN/A
Valuation
PE (TTM|NTM)
-1.29 | -1.47
Above sector avg (-1.50)
P/B Ratio1.34
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue grew 3.84% annually over 5 years — modest growth
Negative free cash flow of -112.35 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7.82%
Price History
Financial Trends
Analyst Price Target
8 analysts
Buy
+417.4%
upside to target
Current
$2.15
Consensus Target
$11.13
$4.00
Low
$32.00
High
Forecast
Forward P/E
-1.47
Forward EPS
-$1.50
Est. Revenue
27.08 M
Earnings Surprises
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -$0.31
·
Rev Est: 2.18 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -$0.44 | -$0.35 | -$0.30 | -$0.28 | — | — |
| Estimate | -$0.45 | -$0.42 | -$0.36 | -$0.32 | -$0.31 | -$0.34 |
| Surprise | +2.22% | +16.67% | +15.95% | +12.89% | — | — |
Growth
Rev 5Y: 3.84% · Earnings 1Y: N/A
Growth
Rev 5Y: 3.84% · Earnings 1Y: N/A| Revenue Growth (1Y) | 11.66% | Revenue Growth (3Y) | -43.11% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 3.84% | Earnings Growth (5Y) | N/A |
Profitability
ROE: -96.19% · Net Margin: -1327.40%
Profitability
ROE: -96.19% · Net Margin: -1327.40%| Revenue (TTM) | 11.16 M | Net Income (TTM) | -148.13 M |
| ROE | -96.19% | ROA | -71.23% |
| Gross Margin | N/A | Operating Margin | -1329.37% |
| Net Margin | -1327.40% | Free Cash Flow (TTM) | -112.35 M |
| ROIC | -65.30% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 5.54
Safety
D/E: N/A · Current: 5.54| Debt / Equity | N/A | Current Ratio | 5.54 |
| Interest Coverage | N/A | Asset Turnover | 0.05 |
| Working Capital | 127.45 M | Tangible Book Value | 141.85 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -1.29 · EV/EBITDA: N/A
Valuation
P/E: -1.29 · EV/EBITDA: N/A| P/E Ratio | -1.29 | Forward P/E | -1.47 |
| P/B Ratio | 1.34 | P/S Ratio | 17.06 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 7.03 | Fwd Earnings Yield | N/A |
| FCF Yield | -59.02% | ||
| Market Cap | 190.38 M | Enterprise Value | 179.23 M |
Per Share
EPS: -1.59 · FCF/Share: -1.16
Per Share
EPS: -1.59 · FCF/Share: -1.16| EPS (Diluted TTM) | -1.59 | Revenue / Share | 0.12 |
| FCF / Share | -1.16 | OCF / Share | -1.15 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 75.85% · CapEx/Rev: 12.18%
Efficiency
FCF Conv: 75.85% · CapEx/Rev: 12.18%| CapEx / Revenue | 12.18% | FCF Conversion | 75.85% |
| SBC-Adj. FCF | -126.36 M | Growth Momentum | 7.82 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.16 M | 9.99 M | 34.48 M | 13.85 M | 9.60 M |
| Net Income | -148.13 M | -149.11 M | -102.07 M | -99.42 M | -66.92 M |
| EPS (Diluted) | -1.59 | -1.65 | -1.38 | -1.64 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -148.34 M | -166.62 M | -116.06 M | -106.40 M | -66.98 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 109.44 M | 130.15 M | 112.08 M | 82.23 M | 52.26 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 3.65 M | 3.93 M | 3.53 M | 1.62 M | 984,000.0 |
| Interest Expense | — | — | — | — | 8,000.0 |
| Income Tax | -550,000.0 | -9,000.0 | 193,000.0 | 70,000.0 | 321,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 175.37 M | 313.31 M | 432.21 M | 373.77 M | 442.36 M |
| Total Liabilities | 53.19 M | 60.36 M | 63.81 M | 72.89 M | 54.53 M |
| Shareholders' Equity | 122.18 M | 252.95 M | 368.40 M | 300.87 M | 387.83 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 12.36 M | 16.29 M | 51.16 M | 58.34 M | 240.42 M |
| Current Assets | 145.23 M | 219.38 M | 338.84 M | 260.25 M | 391.19 M |
| Current Liabilities | 25.41 M | 30.65 M | 28.30 M | 28.13 M | 25.83 M |
Peer Comparison
vs Manufacturing sector median (1605 peers)
Compared with similar companies in Manufacturing
Peer Comparison
vs Manufacturing sector median (1605 peers) Compared with similar companies in Manufacturing| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.3 | -1.5 |
| P/B | 1.3 | 1.6 |
| ROE % | -96.2 | -54.5 |
| Net Margin % | -1327.4 | -41.5 |
| Rev Growth 5Y % | 3.8 | 1.8 |
| D/E | — | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"CRBU","listing_kind":"stock","pathname":"/stocks/crbu","exchange":"NASDAQ","country":"US"}}